Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

de Boer, SM; Powell, ME; Mileshkin, L; Katsaros, D; Bessette, P; Haie-Meder, C; Ottevanger, PB; ... PORTEC study group, .; + view all de Boer, SM; Powell, ME; Mileshkin, L; Katsaros, D; Bessette, P; Haie-Meder, C; Ottevanger, PB; Ledermann, JA; Khaw, P; Colombo, A; Fyles, A; Baron, M-H; Jürgenliemk-Schulz, IM; Kitchener, HC; Nijman, HW; Wilson, G; Brooks, S; Carinelli, S; Provencher, D; Hanzen, C; Lutgens, LCHW; Smit, VTHBM; Singh, N; Do, V; D'Amico, R; Nout, RA; Feeney, A; Verhoeven-Adema, KW; Putter, H; Creutzberg, CL; PORTEC study group, .; - view fewer (2018) Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. The Lancet Oncology , 19 (3) pp. 295-309. 10.1016/S1470-2045(18)30079-2 . Green open access

http://ift.tt/2Idlkx9